Ratings Porton Pharma Solutions Ltd.

Equities

300363

CNE100001S57

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
12.38 ^CNY	-6.00%		-6.35%	-50.78%

05-23	Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024	CI
04-26	Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With a 2024 P/E ratio at 32.58 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PORTON PHARMA SOLUTIONS LTD.	-50.78%	911M	C+
ELI LILLY AND COMPANY	+55.19%	815B	C+
NOVO NORDISK A/S	+46.48%	654B	B
JOHNSON & JOHNSON	-6.09%	354B	C+
MERCK & CO., INC.	+21.92%	337B	B-
ASTRAZENECA PLC	+19.36%	247B	B+
ROCHE HOLDING AG	+3.89%	229B	A+
NOVARTIS AG	+14.08%	219B	B-
AMGEN INC.	+10.86%	171B	C+
PFIZER, INC.	-2.78%	159B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes